Unique ID issued by UMIN | C000000341 |
---|---|
Receipt number | R000000440 |
Scientific Title | Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy |
Date of disclosure of the study information | 2006/03/31 |
Last modified on | 2015/02/22 15:07:08 |
Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy
Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy
Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy
Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy
Japan |
Refractory IgA nephropathy
Medicine in general | Cardiology | Endocrinology and Metabolism |
Nephrology |
Others
NO
We investigate efficacy and safty of mizoribine, prednisolone anti-platelet drug and ARB or ACE inhibitor: four drug combined therapy for refractory IgA nephropathy
Safety,Efficacy
Changing percentage of Ccr and urinary protein.
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Prednisolone and anti-thrombocyte and angiotensin II receptor blocker or angiotensin converting enzyme inhibitor
inhibitor
mizoribine and Prednisolone and anti thrombocyte and angiotensin II receptor blocker or angiotensin-converting enzyme
16 | years-old | <= |
75 | years-old | > |
Male and Female
IgA nephropathy patients who underwent renal biopsy.
Patients who diagnosed to have diffuse IgA nephropathy
Age 16-75 years
Urine protein excretion of over 0.5g daily
patients who's Ccr. Are Under 50ml/min or s-Cr. are over 2.0 mg/dl
patients who have severe liver dysfunction
pregnant or nursing women
patients with a hypersensitivity to each thrapy drugs
Judged inapproopriate for the physicians
60
1st name | |
Middle name | |
Last name | Tetsuya Mitarai |
Saitama Medical Center, Saitama Medical School
Department of Nephrology and Hypertension
1981- Kamoda, Kawagoeshi, SAITAMA 350-8550, JAPAN
049-228-3604
mitarai@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Tetsuya Mitarai |
Japanese Study Group of Multiple drug therapy for IgAN
Department of Nephrology and Hypertension, Saitama Medical Center, Saitama Medical School
1981-Kamoda, Kawagoeshi, Saitama
049-228-3604
mitarai@saitama-med.ac.jp
Japanese Study Group of Multiple drug therapy for IgAN
The kidney Foundation, Japan
Non profit foundation
NO
2006 | Year | 03 | Month | 31 | Day |
Published
Forty five patients, 20 for Group A (corticosteroid, ARB/ACEI, anti-platelet agents) and 25 for Group B (same medications of Group A plus MZB), were analyzed. The baseline characteristics of patients between two groups did not significantly differ.The rate of clinical remission at 12M was significantly higher in group B(40%) than in Group A(7%)(P=0.049), but the difference was no-longer significant at 24M. Multiple-drug combind therapy using MZB may be a useful option for adult patients with intermediate-severrity IgAN.
Completed
2004 | Year | 03 | Month | 01 | Day |
2004 | Year | 04 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
2010 | Year | 12 | Month | 31 | Day |
2011 | Year | 03 | Month | 31 | Day |
2013 | Year | 03 | Month | 31 | Day |
2006 | Year | 02 | Month | 28 | Day |
2015 | Year | 02 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000440
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |